The impact of empagliflozin dose on HbA1c & weight outcomes at 6 & 12 months: updated analysis from the ABCD empagliflozin audit programme
TSJ Crabtree1,2,3, A Gallagher4, I Gallen5, A Melvin6, N Morrish6, J Elliott7, A Bickerton8, REJ Ryder1 on behalf of ABCD empagliflozin audit contributors